Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Noise nags tezampanel

TorreyPines Therapeutics Inc. is not sure why the two higher doses of tezampanel did not meet the endpoint in a Phase IIb trial for acute migraine pain, but the company will forge ahead with Phase III trials using the lowest dose, which did work. When tezampanel goes to FDA, the company believes the low dose's favorable safety profile and clear efficacy signal will outweigh the lack of a dose response.

TorreyPines (TPTX, San Diego, Calif.) also believes it can position the subcutaneous treatment for patients unable to tolerate

Read the full 876 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers